Gene Expression Patterns Associated with Survival in Glioblastoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Apr 13

PMID 38612480

Authors

Christopher Morrison

Eric Weterings

Nicholas Gravbrot

Michael Hammer

Martin Weinand

Abhay Sanan

Ritu Pandey

Daruka Mahadevan

Baldassarre Stea

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate gene expression alterations associated with overall survival (OS) in glioblastoma (GBM). Using the Nanostring nCounter platform, we identified four genes (, and ) that achieved statistical significance when comparing GBM with non-neoplastic brain tissue. The four genes were included in a multivariate Cox Proportional Hazard model, along with age, extent of resection, and O6-methylguanine-DNA methyltransferase ( promotor methylation, to create a unique glioblastoma prognostic index (GPI). The GPI score inversely correlated with survival: patient with a high GPI had a median OS of 7.5 months (18-month OS = 9.7%) whereas patients with a low GPI had a median OS of 20.1 months (18-month OS = 54.5%; log rank -value = 0.004). The GPI score was then validated in 188 GBM patients from The Cancer Genome Atlas (TCGA) from a national data base; similarly, patients with a high GPI had a median OS of 10.5 months (18-month OS = 12.4%) versus 16.9 months (18-month OS = 41.5%) for low GPI (log rank -value = 0.0003). We conclude that this novel mRNA-based prognostic index could be useful in classifying GBM patients into risk groups and refine prognosis estimates to better inform treatment decisions or stratification into clinical trials.

References

Zhou X, Hao Q, Liao P, Luo S, Zhang M, Hu G . Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator. Elife. 2016; 5. PMC: 4943851. DOI: 10.7554/eLife.15099. View

McCord M, Mukouyama Y, Gilbert M, Jackson S . Targeting WNT Signaling for Multifaceted Glioblastoma Therapy. Front Cell Neurosci. 2017; 11:318. PMC: 5645527. DOI: 10.3389/fncel.2017.00318. View

Reis P, Waldron L, Goswami R, Xu W, Xuan Y, Perez-Ordonez B . mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol. 2011; 11:46. PMC: 3103428. DOI: 10.1186/1472-6750-11-46. View

Park J, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A . Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010; 28(24):3838-43. PMC: 2940401. DOI: 10.1200/JCO.2010.30.0582. View

Oelmann E, Sreter L, Schuller I, Serve H, Koenigsmann M, Wiedenmann B . Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling. Cancer Res. 1995; 55(10):2212-9. View

Zhou Q, Yan X, Zhu H, Xin Z, Zhao J, Shen W . Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma. Theranostics. 2021; 11(20):9775-9790. PMC: 8581422. DOI: 10.7150/thno.61677. View

Baxter R . IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014; 14(5):329-41. DOI: 10.1038/nrc3720. View

Li J, Wang M, Won M, Shaw E, Coughlin C, Curran Jr W . Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2010; 81(3):623-30. PMC: 3783211. DOI: 10.1016/j.ijrobp.2010.06.012. View

Suwala A, Hanaford A, Kahlert U, Maciaczyk J . Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy. J Neuropathol Exp Neurol. 2016; 75(5):388-96. DOI: 10.1093/jnen/nlw013. View

10.

Burgenske D, Yang J, Decker P, Kollmeyer T, Kosel M, Mladek A . Molecular profiling of long-term IDH-wildtype glioblastoma survivors. Neuro Oncol. 2019; 21(11):1458-1469. PMC: 6827834. DOI: 10.1093/neuonc/noz129. View

11.

Wang H, Horbinski C, Wu H, Liu Y, Sheng S, Liu J . NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. Nucleic Acids Res. 2016; 44(20):e151. PMC: 5175344. DOI: 10.1093/nar/gkw677. View

12.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

13.

Ahn B, Saldanha-Gama R, Rahn J, Hao X, Zhang J, Dang N . Glioma invasion mediated by the p75 neurotrophin receptor (p75(NTR)/CD271) requires regulated interaction with PDLIM1. Oncogene. 2015; 35(11):1411-22. PMC: 4800290. DOI: 10.1038/onc.2015.199. View

14.

Paravati A, Heron D, Landsittel D, Flickinger J, Mintz A, Chen Y . Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. J Neurooncol. 2010; 104(1):339-49. PMC: 3151374. DOI: 10.1007/s11060-010-0499-8. View

15.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

16.

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

17.

Peng S, Dhruv H, Armstrong B, Salhia B, Legendre C, Kiefer J . Integrated genomic analysis of survival outliers in glioblastoma. Neuro Oncol. 2016; 19(6):833-844. PMC: 5464466. DOI: 10.1093/neuonc/now269. View

18.

Tomfohr J, Lu J, Kepler T . Pathway level analysis of gene expression using singular value decomposition. BMC Bioinformatics. 2005; 6:225. PMC: 1261155. DOI: 10.1186/1471-2105-6-225. View

19.

Lambiv W, Vassallo I, Delorenzi M, Shay T, Diserens A, Misra A . The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 2011; 13(7):736-47. PMC: 3129269. DOI: 10.1093/neuonc/nor036. View

20.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View